Group 1 - A-share market sees weakness in certain biopharmaceutical stocks, with notable declines in several companies [1] - Nanmo Bio falls by 9%, while Shanghai Yizhong drops over 7% [1] - Nocare Health declines by over 5%, and Sunshine Nuohe and Guangshengtang both decrease by over 4% [1] - Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio all experience declines of over 3% [1]

Core Insights - The core viewpoint of the news is the performance and holdings of the E Fund Healthcare Industry Mixed A Fund, highlighting its recent returns and key stock positions [1]. Fund Performance - The latest net value of E Fund Healthcare Industry Mixed A is 4.7830 yuan [1]. - The fund has achieved a weekly return of 3.57% [1]. - Over the past three months, the fund's return is 44.07% [1]. - Year-to-date, the fund has generated a return of 57.03% [1]. Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011 [1]. - As of June 30, 2025, the fund's total assets amount to 3.944 billion yuan [1]. - The fund is managed by Yang Zhenshao [1]. Top Holdings - The top ten stock holdings of the fund include: - Heng Rui Medicine - Hotgen Biotech - Xinlitai - BeiGene-U - Haizhi Science - Nocren Health-U - Yipinhong - Kelun Pharmaceutical - Shutaishen - Baili Tianheng [1]. - The combined proportion of the top ten holdings is 58.14% [1].

Core Viewpoint - The emergence of "technical managers" as a bridge between scientific research and market needs is transforming the employment landscape in the context of technological innovation and entrepreneurship [2][8]. Group 1: Industry Trends - Technology-driven and knowledge-intensive entrepreneurship has become a significant trend in recent years, with many researchers aspiring to transition from PI (Principal Investigator) to IP (Innovation Project) and eventually to IPO (Initial Public Offering) [2]. - The formal recognition of "technical managers" as a profession in the national occupational classification system in 2022 marks a shift towards professionalization and specialization in this role [2][8]. Group 2: Regional Developments - In July 2023, Shenzhen recognized its first batch of 154 "senior professional technical managers" from 133 different institutions, indicating a growing emphasis on this role in the region [3][15]. - The establishment of the first "Technical Manager Academy" at Shenzhen Technology University aims to cultivate a new generation of technical managers, with a focus on interdisciplinary education [14]. Group 3: Challenges in Scientific Entrepreneurship - Many scientists face challenges in entrepreneurship due to a lack of market insight, often focusing solely on technological advancements rather than market needs, leading to high failure rates in startups [5][6]. - The need for effective collaboration between scientists and technical managers is emphasized, as the latter can help translate scientific innovations into commercially viable products [8][11]. Group 4: Educational Initiatives - Several universities, including Tsinghua University and Shanghai Jiao Tong University, have begun offering specialized master's programs in technology transfer to address the shortage of qualified technical managers [14]. - The "Five Forces Model" proposed for training technical managers includes skills in technology, market insight, finance, law, and management, highlighting the multifaceted nature of the role [9][10]. Group 5: Future Outlook - The goal set by the Ministry of Science and Technology is to exceed 30,000 technical managers nationwide by 2025, reflecting the increasing importance of this role in facilitating technology transfer and commercialization [9]. - Shenzhen's dual approach of professional recognition and educational development is expected to provide a model for enhancing technology transfer capabilities across the country [15].

Core Viewpoint - Nocera Biopharma (09969) shares rose over 3%, currently up 3.5% at HKD 18.63, with a trading volume of HKD 133 million, ahead of the board meeting scheduled for August 19 to approve mid-term results [1] Group 1: Financial Performance - Nocera Biopharma's first-quarter revenue increased by 130% year-on-year, with net profit turning positive at HKD 1.8 billion, exceeding expectations due to strong growth of its core product, Oubreti, and confirmation of upfront payment from Prolium [1] - CICC has revised its profit forecasts for Nocera Biopharma, narrowing expected losses for the next two years from HKD 436 million and HKD 256 million to HKD 415 million and HKD 225 million, respectively [1] Group 2: Product Insights - Oubreti, a BTK inhibitor developed by Nocera Biopharma, is primarily used for treating chronic lymphocytic leukemia and is gaining market share, holding a significant position in the domestic BTK inhibitor market [1] - In 2024, Oubreti's sales revenue is projected to exceed HKD 1 billion, representing a year-on-year growth of 49.14%, capturing a 30% market share in the domestic BTK inhibitor market [1]

Core Viewpoint - Nocera Health (09969) has seen a stock increase of over 3%, currently at 18.63 HKD, with a trading volume of 133 million HKD, ahead of its board meeting scheduled for August 19 to approve mid-term results [1] Financial Performance - Nocera Health's first-quarter revenue increased by 130% year-on-year, with net profit turning positive at 1.8 billion HKD, exceeding expectations due to strong growth of its core product, Oubreti [1] - CICC has revised its profit forecasts for Nocera Health, narrowing expected losses for the next two years from 436 million HKD and 256 million HKD to 415 million HKD and 225 million HKD respectively [1] Product Insights - Oubreti, a BTK inhibitor developed by Nocera Health, is primarily used for treating chronic lymphocytic leukemia and has been gaining market share, holding a significant position in the domestic BTK inhibitor market [1] - In 2024, Oubreti's sales revenue is projected to exceed 1 billion HKD, representing a year-on-year growth of 49.14%, capturing a 30% market share in the domestic BTK inhibitor market [1]

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown significant performance with a recent net value of 4.5530 CNY, despite a slight decline of 1.73% [1] Performance Summary - The fund's one-month return is 12.81%, ranking 628 out of 4566 in its category [1] - Over the past six months, the fund has achieved a return of 48.74%, ranking 108 out of 4413 [1] - Year-to-date, the fund's return stands at 49.47%, with a ranking of 158 out of 4375 [1] Holdings Summary - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14%, with the following key positions: - Heng Rui Medicine: 7.39% - Rejing Biology: 7.00% - Xinlitai: 6.73% - BeiGene-U: 6.47% - Haizhi Science: 6.00% - Nocren Health-U: 5.21% - Yipinhong: 5.08% - Kelun Pharmaceutical: 5.07% - Shutaishen: 5.05% - Baili Tianheng: 4.14% [1] Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]

Investment Rating - The industry investment rating is "Outperform the Market" [1][47]. Core Insights - The white spot market for vitiligo treatment is vast, with a potential market size expected to reach 21.7 billion yuan by 2030, driven by an increasing number of patients and the need for effective treatments [3][15][39]. - Current treatment options are inadequate, with no approved products specifically for vitiligo in China, highlighting a significant gap in the market that innovative drugs could fill [3][26]. - The competitive landscape is favorable, with several small pharmaceutical companies and leading firms vying for market share, and key products expected to receive approval soon [3][39]. Summary by Sections Part 1: Patient Demographics and Health Risks - The prevalence of vitiligo is significant, with approximately 22.83 million patients in China, of which 54.01% are receiving treatment [3][15]. - The condition is associated with severe psychological impacts, including a higher incidence of depression among patients [3][10]. Part 2: Current Treatment Limitations - Existing treatments, primarily involving drug therapy and phototherapy, have shown limited effectiveness, necessitating the introduction of new drugs with higher repigmentation rates [3][24]. - The current market lacks approved medications specifically for vitiligo, with existing drugs primarily approved for other conditions [3][26]. Part 3: Competitive Landscape and Drug Development - The vitiligo treatment sector is characterized by a lack of approved products, with several drugs in various stages of clinical trials, including one in Phase III and six in Phase II [3][39]. - JAK inhibitors are identified as key targets in drug development, with the first approved topical JAK1/JAK2 inhibitor, Ruxolitinib cream, showing promising sales growth [3][32][39]. - The innovative drug market for vitiligo is projected to reach 10 billion yuan, with significant interest in companies like Kangzheng Pharmaceutical and TianKang [3][39]. Part 4: Investment Recommendations - The report suggests focusing on the progress of drug development in the vitiligo sector and monitoring companies involved, including Kangzheng Pharmaceutical, TianKang, Huadong Medicine, and others [3][39].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资者可于2025年8月13日(星期三)至8月19日(星期二)16:00前登录上证路演中心网站首页点击"提问预 征集"栏目或通过公司邮箱IR@innocarepharma.com进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答 诺诚健华医药有限公司（以下简称"公司"）将于2025年8月20日发布公司2025年半年度报告，为便于广 大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年8月20日上午 11:00-12:00举行2025年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 登录新浪财经APP 搜索【信披】查看更多考评等级 A股代码：688428 A股简称：诺诚健华 公告编号：2025-027 港股代码：09969 港股简称：诺诚健华 诺诚健华医药有限公司关于召开2025年半年度业绩说明会的公告 （如有特殊情况，参会人员可能进行调整） 四、投资者参加方式 （一）投资者可在2025年8月20日上午11 ...

A 股代码：688428 A 股简称：诺诚健华 公告编号：2025-027 港股代码：09969 港股简称：诺诚健华 诺诚健华医药有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一） 会议召开时间：2025 年 8 月 20 日上午 11:00-12:00 重要内容提示： ? 会议召开时间：2025 年 8 月 20 日(星期三)上午 11:00-12:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 2025 年 8 月 13 日(星期三)至 8 月 19 日(星期二)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答 诺诚健华医药有限公司（以下简称"公司"）将于 2025 年 8 月 20 日发布公 司 2025 ...

（文章来源：证券日报） 证券日报网讯 8月11日晚间，诺诚健华发布公告称，公司将于2025年8月20日举行2025年半年度业绩说 明会。 ...